NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Nicotinamide riboside (Primary)
- Indications Mild cognitive impairment
- Focus Therapeutic Use
- 13 Mar 2025 According to ChromaDex Corporation media release, ChromaDex Corp has changed its name to Niagen Bioscience.
- 22 Jan 2024 Status changed from active, no longer recruiting to completed.
- 09 Oct 2023 Status changed from recruiting to active, no longer recruiting.